Key Points Eli Lilly was second to market with a GLP-1 drug, but it quickly became the industry leader. The company recognizes that patents will only protect its GLP-1 drugs for just so long. The company, like its peers, is always on the lookout for blockbuster new drugs. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) has seen huge success in the GLP-1 weight-loss drug space with Mounjaro and Zepbound. Although it was second to market after Novo Nordisk (NYSE: NVO) in the GLP-1 space, better patient outcomes and Novo Nordisk's inability to keep up with demand enabled Eli Lilly to take the industry lead.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.